Literature DB >> 16325705

Time course and morphology of vascular effects associated with photodynamic therapy.

Ursula Schmidt-Erfurth1, Marc Niemeyer, Wolfgang Geitzenauer, Stephan Michels.   

Abstract

PURPOSE: To evaluate the time course and morphologic features of verteporfin therapy-induced vascular effects using 3-dimensional topographic angiography (TAG) in patients with choroidal neovascularization (CNV).
DESIGN: Prospective observational case series. PARTICIPANTS: Fifty-three eyes of 53 patients with neovascular age-related macular degeneration and Treatment of Age-Related Macular Degeneration with Photodynamic Therapy/Verteporfin in Photodynamic Therapy characteristics were treated with verteporfin therapy using standard parameters.
METHODS: Treatment effects were evaluated before and at 5 hours, 1 day, 1 week, and 3 months after treatment by serial confocal fluorescein angiography (FA) and indocyanine green angiography (ICGA). The axial distribution of fluorescence at each x-position and y-position within a tomographic scan of 32 images over a depth of 4 mm was analyzed, and a 3-dimensional profile was generated. Changes at the level of the CNV lesion and the collateral choroid were documented over time with respect to vascular closure, leakage resulting from vascular barrier breakdown, and alteration of physiologic perfusion. MAIN OUTCOME MEASURES: Three-dimensional imaging of exudation and nonperfusion.
RESULTS: At baseline, 3-dimensional FA and ICGA imaging demonstrated a well-defined prominent CNV complex. At 5 hours after verteporfin therapy, 3-dimensional FA identified an extensive increase in hyperfluorescent prominence as well as lesion extension in most verteporfin-treated eyes (65%), resulting from increased permeability and leakage due to a vascular barrier breakdown in the collateral choroid. Massive exudation throughout the entire light-exposed area was still noted in most eyes 1 day after treatment. At 1 week, the exudative response, seen in 3-dimensional imaging, had diminished substantially. Simultaneously, documented best by 3-dimensional ICGA, TAG demonstrated perfusion defects within the adjacent choroid, which started as early as 1 day after verteporfin therapy and persisted during extended follow-up. Three-dimensional angiography identified the morphologic features of hyperfluorescence and hypofluorescence more realistically than conventional angiography.
CONCLUSIONS: Three-dimensional angiography demonstrates a characteristic sequence of changes in the vascular architecture of the CNV lesion and the collateral choroid after verteporfin therapy. Choroidal neovascularization occlusion is associated with immediate massive exudation and is followed by occlusive effects within the collateral choroid. Knowledge of the time course and mechanisms of phototoxic events should help to develop appropriate combination treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325705     DOI: 10.1016/j.ophtha.2005.09.007

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  23 in total

1.  Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration.

Authors:  Miki Sawa; Eiji Iwata; Kohei Ishikawa; Fumi Gomi; Kohji Nishida; Hiroko Terasaki
Journal:  Jpn J Ophthalmol       Date:  2012-06-09       Impact factor: 2.447

2.  Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degeneration.

Authors:  Taylan Ozturk; Hakan Oner; Ali Osman Saatci; Suleyman Kaynak
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

3.  Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy.

Authors:  Matthew R Ritter; Eyal Banin; Stacey K Moreno; Edith Aguilar; Michael I Dorrell; Martin Friedlander
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

Review 4.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

5.  Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro.

Authors:  R Obata; A Iriyama; Y Inoue; H Takahashi; Y Tamaki; Y Yanagi
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

6.  Treatment of myopic choroidal neovascularization with posterior sub-Tenon's bevacizumab injection (Avastin ®).

Authors:  I-Chia Liang; Yu-Ying Chang; Tong-Sheng Lee; Yi-Ru Lin; Kwan-Rong Liu
Journal:  Int Ophthalmol       Date:  2014-02-02       Impact factor: 2.031

7.  Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models.

Authors:  Kimberley S Samkoe; Alina Chen; Imran Rizvi; Julia A O'Hara; P Jack Hoopes; Stephen P Pereira; Tayyaba Hasan; Brian W Pogue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

Review 8.  Intraocular sustained-release delivery systems for triamcinolone acetonide.

Authors:  Saffar Mansoor; Baruch D Kuppermann; M Cristina Kenney
Journal:  Pharm Res       Date:  2009-01-28       Impact factor: 4.200

Review 9.  Combination of photodynamic therapy and immunomodulation: current status and future trends.

Authors:  Yong-Gang Qiang; Christine M N Yow; Zheng Huang
Journal:  Med Res Rev       Date:  2008-07       Impact factor: 12.944

10.  Histopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: report of two cases.

Authors:  S J Kang; I Schmack; H E Benson; H E Grossniklaus
Journal:  Br J Ophthalmol       Date:  2007-06-13       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.